Metastasis: An Overview
Metastasis means the spread of the malignant cells from the origin site to a distant area. It involves the process of separation / detachment, transportation of fragmented primary tumour cell and lodging in the new site, having a favourable environment. It does not result from random survival of cells released from the primary tumour, but from the selective growth of specialised subpopulations of highly metastatic cells endowed with specific properties that benefit them to complete each step of the metastatic process. To understand this complex network we need to explore the molecules involved in it. This article reviews the theories, mechanisms, genes and genetic alterations that are involved in the process of metastasis.
Weiss L. Metastasis of cancer: a conceptual history from antiquity to the 1990s. Cancer Metast Rev (2000). 19: 193–383.
Klein CA (September 2008). “Cancer. The metastasis cascade”. Science (2008). 321 (5897):1785–7.
Willis AA. The direct spread of tumours. In: Willis RA, ed. The spread of tumours in the human body. London: Butterworth (1973).1-17
Liotta LA, Stetler-Stevenson WG. Principles of molecular cell biology of cancer: cancer metastasis. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: principles andpractice ofoncology. Philadelphia: Lippincott (1989). 98-115.
Paget S. The distribution of secondary growths in cancer of the breast. Lancet (1889). 1:571-73.
Ewing J. A treatise on tumors; 3rd ed. Philadelphia: Saunders (1928).
McGowa n PM, K i rstei n J M, Chambers A F. Micrometastatic disease and metastatic outgrowth: clinical issues and experimental approaches. Future Oncol (2009). 5: 1083–98.
Chambers A F, Groom, AC, MacDonald, IC . Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer (2002). 2:563–72.
Guo, W, Giancotti, FG . Integrin signalling during tumour progression. Nat. Rev. Mol Cell Biol (2004). 5: 816–26.
Wicki A, Lehembre F, Wick N, Hantusc, B, Kerjaschki D, Christofori G. Tumor invasion in the absence of epithelialmesenchymal transition: podoplanin-mediated remodeling of the actin cytoskeleton. Cancer Cell (2006). 9:261–72.
Netland PA, Zetter BA. Tumor-cell interactions with blood vessels during cancer metastasis. In: Goldfarb RH, ed. Fundamental aspects of cancer .The Netherlands: Kluwer (1989). 84-93.
MacDonald NJ, Steeg PA. Molecular basis of tumour metastasis. Cancer Surv (1993). 16:175-99.
Sporn MB, Todaro GJ. Autocrine secretion and malignant transformation of cells. N EngI J Med (1980). 303:878-80.
Carter AL General pathology of the metastatic process. In: Baldwin AW, ad. Secondary spread ofcancer. San Diego, CA: Academic Press (1978). pp1-52.
Morgan Parkes JH. Metastases mechanisms, pathways and cascades. Advances in clinical medicine.(1995). 164(5):1075-82.
Fisher G, Fisher E. Significance of the interrelationship of the lymph and blood vascular systems in tumor cell dissemination. Prog Clin Cancer (1968). 84-96.
Kaiser HE. Spreading by implantation on epithelial surfaces and iatrogenic spreading by implantation. In: Brunson KW, ed. Local invasion and spread of cancer. volume 7. The Netherlands: Ktluwer (1988). 7:pp.38-41
Nowell PC The clonal evolution of tumour cell populations. Science (1976). 194:23-8.
Forastiere MDA, Koch W et al .Head and Neck cancer in the United States (1975-1998).
Van Oijen MGCT, Pieter J. Oral field cancerization: Carcinogen-induced independent events or micrometastatic deposits? Cancer Epidemiol, Biomarkers Prev (2000). 9: 249–56.
Devita, Principles of Oncology 7th edition, Lippincott Publication. (2011). pp509-634.
Hartsough MT, Morrison DK, Salerno M, Palmieri D, Ouatas T, Mair M et al. Nm23- H1 metastasis suppressor phosphorylation of kinase suppressor of Ras via a histidine protein kinase pathway. J Biol Chem (2002). 277-81.
Belev B, Aleric I, Vrbanec D, Petrovecki M, Unusic J, Jakic-Razumovic J. Nm23 gene product expression in invasive breast cancer--immunohistochemical analysis and clinicopathological correlation. Acta. Oncol (2002). 41:355–61.
Lee JH, Miele ME, Hicks DJ, Phillips KK, Trent JM, Weissman BE, et al. KiSS-1, a novel human malignant melanoma metastasis-suppressor gene. J. Natl. Cancer Inst (1996). 88:1731–37.
Ohtaki T, Shintani Y, Honda S, Matsumoto H, Hori A, Kanehashi K et al. Metastasis suppressor gene KiSS-1 encodes peptide ligand of a G-protein-coupled receptor. Nature (2001). 411:613–17.
Yoshida BA, Dubauskas Z, Chekmareva MA, Christiano TR, Stadler WM, Rinker-Schaeffer CW. Mitogen-activated protein kinase kinase 4 / stress activated protein / Erk kinase 1 (MKK4 / SEK1), a prostate cancer metastasis suppressor gene encoded by human chromosome 17. Cancer Res (1999). 59:5483–7.
Kauffman EC, Robinson VL, Stadler WM, Sokoloff MH, Rinker-Schaeffer CW. Metastasis suppression: the evolving role of metastasis suppressor genes for regulating cancer cell growth at the secondary site. J. Urol (2003). 169:1122–33.
Takeichi M. The cadherins: cell-cell adhesion molecules controlling animal morphogenesis. Development (1988). 102:639–55.
Tomita K, van Bokhoven A, van Leenders GJ, Ruijter ET, Jansen CF, Bussemakers MJ,etal. Cadherin switching in human prostate cancer progression. Cancer Res (2000). 60:3650–3654.
Van Belzen N, Dinjens WN, Diesveld MP, Groen NA, van der Made AC, Nozawa Y, et al. A novel gene which is up-regulated during colon epithelial cell differentiation and down-regulated in colorectal neoplasms. Lab. Invest (1997). 77:85–92.
Bandyopadhyay S, Pai SK, Gross SC, Hirota S, Hosobe S, Miura K et al. The Drg-1 gene suppresses tumor metastasis in prostate cancer. Cancer Res (2003). 63:1731–36.
Hershko C. Control of disease by selective iron depletion: a novel therapeutic strategy utilizing iron chelators. Baillieres. Clin. Haematol (1994). 7:965– 1000.
Whitnall M, Howard J, Ponka P, Richardson DR. A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics. Proc. Natl. Acad. Sci. U. S. A (2006). 103:14901–6.
Iiizumi M, Liu W, Pai SK, Furuta E. Drug development against metastasis-related genes and their pathways: A rationale for cancer therapy Biochim Biophys Acta. (2008). 1786(2): 87–104